10-K: Nektar Therapeutics Reports 2024 Financial Results, Highlights Pipeline Progress

Nektar Therapeutics details its 2024 financial performance and provides updates on its key drug development programs, including rezpegaldesleukin and NKTR-255.

Summary

• Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines in immunotherapy.
• The company's pipeline includes clinical-stage and preclinical-stage immunomodulatory agents targeting autoimmune diseases and cancer.
• Key drug candidates include rezpegaldesleukin for autoimmune diseases and NKTR-255 for cancer.
• In December 2024, Nektar sold its manufacturing facility in Huntsville, Alabama, to Gannet BioChem for $64.7 million in cash and an equity interest in Gannet BioChem.
• The company initiated a Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis, with topline data expected in the first half of 2025.
• A Phase 2b clinical study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata was also initiated, with topline data expected in the second half of 2025.
• The FDA granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis.
• Nektar is collaborating with Merck KGaA to evaluate NKTR-255 in combination with avelumab in patients with urothelial carcinoma, with topline data expected in the first half of 2025.
• A new clinical study collaboration was established with AbelZeta Pharma to study NKTR-255 in combination with its C-TIL051 in advanced non-small cell lung cancer patients.
• Research and development expenses for 2024 were $120.9 million, compared to $114.2 million in 2023.
• The company reported a net loss of $119.0 million for 2024, compared to a net loss of $276.1 million for 2023.
• As of December 31, 2024, Nektar had cash and investments in marketable securities valued at approximately $269.1 million.
• The company estimates it has working capital to fund its current business plans through at least the next twelve months.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there are positive developments in the pipeline and a decrease in net loss compared to the previous year. The sale of the manufacturing facility also strengthens the company's financial position.

Positives

• FDA granted Fast Track designation for rezpegaldesleukin in atopic dermatitis, potentially expediting its development and review.
• New clinical study collaboration with AbelZeta Pharma to study NKTR-255 in combination with C-TIL051 in advanced non-small cell lung cancer patients.
• Sale of the Huntsville manufacturing facility generated $64.7 million in cash and an equity interest, strengthening the company's financial position.
• Net loss decreased significantly from $276.1 million in 2023 to $119.0 million in 2024, indicating improved financial management.
• Cash and investments in marketable securities remain strong at $269.1 million, providing a solid foundation for ongoing research and development.

Negatives

• The company continues to incur substantial losses and negative cash flow from operations.
• The success of the company is highly dependent on the clinical success of rezpegaldesleukin and NKTR-255.
• The company faces intense competition in the pharmaceutical and biotechnology industry.
• The company relies on third parties to conduct preclinical studies and clinical trials for its drug candidates.

Risks

• Clinical drug development is a lengthy and uncertain process, and there is no guarantee that drug candidates will be successful.
• The company is highly dependent on the success of rezpegaldesleukin, and its business will be significantly harmed if it does not continue to advance in clinical studies.
• Significant competition for products and drug candidates could make drug products or drug candidates obsolete or uncompetitive.
• The company has substantial future capital requirements and there is a risk it may not have access to sufficient capital to meet its current business plan.
• The company relies on contract manufacturers, and any failure to manufacture drugs or drug substances in sufficient quantities could harm the business.
• The company purchases some starting material for drugs and drug candidates from a single source or a limited number of suppliers, and the loss of one of these suppliers could cause delays.
• The company or its partners may not obtain regulatory approval for drug candidates on a timely basis, or at all.
• Patents may not issue from patent applications, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required.
• The company is involved in legal proceedings and may incur substantial litigation costs and liabilities.

Future Outlook

The company expects to continue to invest in its pipeline of drug candidates and to seek partnerships to fund a portion of its research and development capital requirements. Topline data from the Phase 2b clinical study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis is expected in the first half of 2025. Topline data from the Phase 2b clinical study of rezpegaldesleukin in patients with severe-to-very severe alopecia areata is expected in the second half of 2025. Topline data from the Phase II JAVELIN Bladder Medley study is expected in the first half of 2025.

Management Comments

• We continue to make significant investments in building and advancing our pipeline of drug candidates as we believe that this is the best strategy to build long-term shareholder value.

Industry Context

The announcement reflects the ongoing trend in the biopharmaceutical industry of focusing on immunotherapy and developing targeted treatments for autoimmune diseases and cancer. The company's collaborations and pipeline progress are consistent with industry efforts to innovate and address unmet medical needs.

Comparison to Industry Standards

• Nektar's focus on immunotherapy aligns with companies like Bristol Myers Squibb, Merck, and Roche, which are heavily invested in this area.
• The development of rezpegaldesleukin for autoimmune diseases is comparable to efforts by companies like Amgen and UCB Pharma, which have marketed products for similar indications.
• The collaboration with AbelZeta Pharma to study NKTR-255 in combination with C-TIL051 is similar to other partnerships in the cell therapy space, such as those between Kite Pharma and various research institutions.
• The sale of the manufacturing facility is a common strategy among biopharmaceutical companies to streamline operations and focus on core research and development activities, similar to moves made by Amgen and Biogen in recent years.
• The company's research and development expenses are in line with other clinical-stage biopharmaceutical companies of similar size and focus.

Legal Proceedings

• The company is involved in legal proceedings with Eli Lilly and Company, alleging breach of contract and breach of implied covenant of good faith and fair dealing.

Related Party Transactions

• The company sold its manufacturing facility to Gannet BioChem, an affiliate of Ampersand Management LLC.
• The company has supply agreements and services agreements with Gannet BioChem.
• Sandra Gardiner, the Interim Chief Financial Officer, is a partner at FLG Partners, LLC, and the company pays FLG Partners for her consulting services.

Stakeholder Impact

• Shareholders: The company's financial performance and pipeline progress will impact shareholder value.
• Employees: The company's restructuring plans and workforce reductions have impacted employees.
• Patients: The company's drug development programs have the potential to provide new treatment options for patients with autoimmune diseases and cancer.
• Collaboration Partners: The company's collaborations with other pharmaceutical and biotechnology companies are important for funding and developing its drug candidates.

Next Steps

• Continue clinical development of rezpegaldesleukin in atopic dermatitis and alopecia areata, with topline data expected in 2025.
• Advance NKTR-255 for strategic partnerships and continue select developmental studies in combination with cell therapies and checkpoint inhibitors.
• Continue IND enabling activities for NKTR-0165, with the goal of preparing for an IND submission in the second half of 2025.
• Seek new collaboration agreements to fund a portion of research and development capital requirements.

Key Dates